NCT02991651View on ClinicalTrials.gov

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

PHASE1TerminatedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

December 7, 2016

Primary Completion Date

May 9, 2025

Study Completion Date

May 9, 2025

Conditions

Lung Cancer, Nonsmall Cell

Interventions

DRUG

IRX4204

RXR agonist

DRUG

erlotinib

inhibitor of phosphorylation of the tyrosine kinase associated with the epidermal growth factor receptor

Trial Locations (1)

03756

Geisel School of Medicine at Dartmouth, Lebanon

Sponsors

Lead Sponsor

Io Therapeutics

All Listed Sponsors

collaborator

Dartmouth College

OTHER

lead

Io Therapeutics

INDUSTRY